| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10967146 | Vaccine | 2014 | 6 Pages |
Abstract
This study in children younger than 5 years, 90% of them between 11 and 23 months, shows a risk of FC similar in magnitude for Priorix-Tetra⢠as has previously been reported for ProQuad® suggesting a class effect for these quadrivalent vaccines.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Tania Schink, Jakob Holstiege, Frank Kowalzik, Fred Zepp, Edeltraut Garbe,